Suchanek P, Lorenzova A, Poledne R, Hubacek J A
Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Ann Nutr Metab. 2008;53(2):104-8. doi: 10.1159/000165358. Epub 2008 Oct 22.
Apolipoprotein A5 (APOA5) is a determinant of plasma lipids, and its role in body mass index (BMI) determination is discussed. This study was aimed at the investigation of the relationship between common APOA5 gene variants and body weight/plasma lipid decrease in overweight females.
We analyzed 98 unrelated overweight and obese nondiabetic Czech females (BMI >27.5). APOA5 T-1131-->C and Ser19-->Trp variants were genotyped. Before and after 9 weeks of lifestyle modification, biochemical and anthropometrical measurements and assessment of nutritional intake were performed. The lifestyle modification program consisted of a reduction in energy intake and an exercise program (aerobic exercise 4 times per week, 60 min each).
The mean age of the participants was 30.7 +/- 3.7 years, the mean BMI before the intervention was 31.4 +/- 3.8 and the weight loss was 5.9 +/- 2.5 kg (7 +/- 3%). There were 86 T-1131T homozygotes and 12 carriers of the C-1131 allele and 82 Ser19Ser homozygotes and 16 carriers of the Trp19 allele, respectively; 72 females had the commonest T-1131T/Ser19Ser haplotype. No significant association between BMI decrease and APOA5 variants was found, but T-1131T carriers have a significantly higher body weight both before and after the intervention (p < 0.05; p = not significant for BMI). The fasting glycemia was significantly higher in Trp19 carriers both before and after the intervention (p < 0.01). Further, plasma triglyceride levels decreased in Ser19Ser homozygotes but increased in Trp19 carriers (1.42 +/- 0.62 to 1.28 +/- 0.48 vs. 1.15 +/- 0.47 to 1.41 +/- 0.80 mmol/l; p < 0.05 for differences between the groups). Similarly, in carriers of at least 1 less common APOA5 allele (n = 26), plasma low-density lipoprotein cholesterol levels did not decrease as they did in T-1131T/Ser19Ser carriers (3.11 +/- 0.70 to 3.27 +/- 0.81 vs. 3.39 +/- 0.81 to 3.16 +/- 0.86 mmol/l; p < 0.05 for differences between the groups).
APOA5 gene variants have effects on the decrease in plasma triglyceride and low-density lipoprotein cholesterol level in females in a model combining their dietary habits and physical activity changes.
载脂蛋白A5(APOA5)是血浆脂质的一个决定因素,其在体重指数(BMI)测定中的作用也备受讨论。本研究旨在调查常见APOA5基因变异与超重女性体重/血浆脂质降低之间的关系。
我们分析了98名无亲缘关系的超重且非糖尿病的捷克女性(BMI>27.5)。对APOA5基因T-1131→C和Ser19→Trp变异进行基因分型。在生活方式改变9周前后,进行生化和人体测量,并评估营养摄入情况。生活方式改变计划包括减少能量摄入和一项运动计划(每周进行4次有氧运动,每次60分钟)。
参与者的平均年龄为30.7±3.7岁,干预前的平均BMI为31.4±3.8,体重减轻了5.9±2.5 kg(7±3%)。分别有86名T-1131T纯合子和12名C-1131等位基因携带者,以及82名Ser19Ser纯合子和16名Trp19等位基因携带者;72名女性具有最常见的T-1131T/Ser19Ser单倍型。未发现BMI降低与APOA5变异之间存在显著关联,但T-1131T携带者在干预前后的体重均显著更高(p<0.05;BMI无显著差异)。Trp19携带者在干预前后的空腹血糖均显著更高(p<0.01)。此外,Ser19Ser纯合子的血浆甘油三酯水平降低,而Trp19携带者的血浆甘油三酯水平升高(1.42±0.62至1.28±0.48 vs. 1.15±0.47至1.41±0.80 mmol/L;两组间差异p<0.05)。同样,在至少携带1个较不常见APOA5等位基因的携带者(n = 26)中,血浆低密度脂蛋白胆固醇水平并未像T-1131T/Ser19Ser携带者那样降低(3.11±0.70至3.27±0.81 vs. 3.39±0.81至3.16±0.86 mmol/L;两组间差异p<0.05)。
在结合饮食习惯和身体活动变化的模型中,APOA5基因变异对女性血浆甘油三酯和低密度脂蛋白胆固醇水平的降低有影响。